|
The Company’s net revenue and cost of revenue and goods sold as shown on the consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands):
|
|
|
Year Ended December 31, |
|
|
|
|
2022 |
|
|
2021 |
|
|
2020 |
|
|
Net revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
Product sales (1) |
|
|
81,073 |
|
|
|
39,435 |
|
|
|
32,324 |
|
|
Services (2) |
|
|
3,098 |
|
|
|
36,007 |
|
|
|
32,820 |
|
|
Royalties (3) |
|
|
15,599 |
|
|
|
— |
|
|
|
— |
|
|
Total net revenue |
|
$ |
99,770 |
|
|
$ |
75,442 |
|
|
$ |
65,144 |
|
_________________________
|
(1) |
Amounts represent the net sales of Afrezza and V-Go to wholesalers and specialty pharmacies and Tyvaso DPI to UT. |
|
(2) |
Amounts represent revenue generated from the Company’s collaboration arrangements, including Next-Gen R&D Services (as defined in Note 11) for UT as well as arrangements with other collaboration partners. See Note 11 – Collaboration, Licensing and Other Arrangements. |
|
(3) |
Amounts represent royalties on UT’s net sales of Tyvaso DPI. |
|
|
|
Year Ended December 31, |
|
|
|
|
2022 |
|
|
2021 |
|
|
2020 |
|
|
Cost of goods sold and cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
Product sales |
|
$ |
55,071 |
|
|
$ |
16,833 |
|
|
$ |
15,084 |
|
|
Services |
|
|
2,426 |
|
|
|
22,024 |
|
|
|
9,557 |
|
|
Total cost of goods sold and cost of revenue |
|
$ |
57,497 |
|
|
$ |
38,857 |
|
|
$ |
24,641 |
|
|